The business is stabilizing, but it's still working through past mistakes.
Cardlytics shares have been on a wild ride this March. Should investors follow suit with massive insider buying, or steer clear of this highly volatile small-cap stock?
News of a fresh round of financing made many investors rather unhappy.
Wall Street is surprised to watch this company come to life after it was left for dead.
The company is moving past one of its bigger headwinds.
The consensus price target hints at a 49.3% upside potential for Cardlytics (CDLX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...
Cardlytics (CDLX) delivered earnings and revenue surprises of 37.50% and 4.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?